ANAPC15 Antibody

What is ANAPC15 and what cellular functions does it perform?

ANAPC15 (Anaphase-Promoting Complex Subunit 15) functions as a component of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated E3 ubiquitin ligase that controls progression through mitosis and the G1 phase of the cell cycle. While not directly required for APC/C activity itself, ANAPC15 plays a crucial role in the release of the mitotic checkpoint complex (MCC) from the APC/C, promoting the turnover of CDC20 and MCC on the APC/C. This function contributes to the responsiveness of the spindle assembly checkpoint. Additionally, ANAPC15 is required for the degradation of CDC20 .

What types of ANAPC15 antibodies are currently available for research applications?

The majority of commercially available ANAPC15 antibodies are polyclonal antibodies raised in rabbits using synthetic peptides of human ANAPC15 as immunogens. These antibodies typically demonstrate reactivity with human, mouse, and rat ANAPC15, making them versatile for cross-species research. They are generally supplied in unconjugated forms with concentrations around 1.2 mg/mL in buffers containing PBS with preservatives like sodium azide (0.05%) and stabilizers such as glycerol (40%) . Multiple validated antibodies are available from different providers, each optimized for specific research applications including Western blotting, immunohistochemistry, and ELISA .

What are the optimal storage and handling conditions for ANAPC15 antibodies?

For maximum stability and performance, ANAPC15 antibodies should be stored at -20°C and protected from repeated freeze-thaw cycles which can degrade antibody functionality. Most commercial preparations are shipped frozen and should be maintained in aliquots to minimize freeze-thaw events. When working with the antibody, thaw aliquots on ice or at 4°C rather than at room temperature. The typical buffer composition (PBS with NaN₃ and glycerol) helps maintain stability, but additional precautions should be taken to avoid bacterial contamination during handling .

What are the recommended dilutions and applications for ANAPC15 antibodies?

Based on current research protocols, ANAPC15 antibodies can be effectively utilized across multiple applications with the following recommended dilutions:

These recommendations serve as starting points, and researchers should perform optimization experiments to determine the ideal conditions for their specific experimental setup, tissue type, and detection system .

How can I validate the specificity of ANAPC15 antibodies for my research?

Validating antibody specificity is critical for generating reliable research data. For ANAPC15 antibodies, implement a multi-faceted validation approach:

• Perform Western blotting to confirm detection of a single band at the expected molecular weight of ANAPC15

• Include positive controls (cell lines/tissues known to express ANAPC15) and negative controls (ANAPC15 knockdown/knockout samples)

• Conduct peptide competition assays using the immunizing peptide to confirm binding specificity

• Compare results across multiple ANAPC15 antibodies targeting different epitopes

• Correlate protein detection with mRNA expression data from RT-PCR or RNA-seq

• Test cross-reactivity across human, mouse, and rat samples if working with multiple species

This comprehensive validation strategy ensures that experimental results truly reflect ANAPC15 biology rather than non-specific antibody interactions .

What optimization strategies can improve ANAPC15 antibody performance in immunohistochemistry?

Optimizing immunohistochemistry protocols for ANAPC15 antibodies requires systematic adjustment of several parameters:

• Antigen retrieval: Test both heat-induced epitope retrieval (citrate buffer pH 6.0 or EDTA buffer pH 9.0) and enzymatic retrieval methods to determine which best exposes the ANAPC15 epitope

• Blocking conditions: Optimize blocking agent (BSA, normal serum, commercial blockers) concentration and incubation time to minimize background without compromising specific signal

• Antibody concentration: Perform a dilution series starting with manufacturer recommendations (typically 1:40-1:200 for IHC)

• Incubation conditions: Compare overnight incubation at 4°C versus shorter incubations at room temperature

• Detection system: For low-abundance ANAPC15, consider signal amplification methods such as polymer-based detection systems or tyramide signal amplification

• Controls: Always include tissue sections without primary antibody and positive control tissues with known ANAPC15 expression patterns

Systematic optimization of these variables will yield reproducible, specific staining patterns for ANAPC15 in tissue sections .

What is the significance of anti-ANAPC15 autoantibodies in rheumatoid arthritis diagnosis?

Recent genome-wide protein array screening has identified anti-ANAPC15 autoantibodies as potential diagnostic biomarkers for rheumatoid arthritis (RA), with particular relevance for anti-citrullinated protein antibody (ACPA)-negative RA patients who currently lack specific diagnostic markers. In comprehensive validation studies, anti-ANAPC15 demonstrated remarkable specificity (91.5%) with a sensitivity of 41.8% among total RA patients. The area under the curve (AUC) value was 0.788, indicating good discriminatory power for diagnostic purposes .

The clinical significance is particularly notable for ACPA-negative RA patients, where anti-ANAPC15 showed a prevalence of 20.8% while maintaining its high specificity (91.5%). This performance positions anti-ANAPC15 as one of the more promising biomarkers for this difficult-to-diagnose patient subgroup .

How does anti-ANAPC15 perform compared to other novel autoantibodies in RA diagnosis?

Comparative analysis of autoantibodies identified in RA patients reveals distinct performance characteristics:

How can researchers effectively incorporate anti-ANAPC15 detection into multi-biomarker approaches for RA diagnosis?

To effectively incorporate anti-ANAPC15 into multi-biomarker diagnostic approaches for RA, researchers should consider:

• Developing standardized ELISA protocols using recombinant ANAPC15 protein as the capture antigen to ensure consistent detection of anti-ANAPC15 autoantibodies

• Creating a weighted algorithm that accounts for the relative diagnostic value of each biomarker based on their individual performance characteristics

• Establishing clear positivity thresholds that prioritize specificity (>90%) while maximizing sensitivity

• Validating the multi-biomarker panel in diverse patient populations, including early RA and ACPA-negative patients

• Assessing complementarity with existing diagnostic criteria and biomarkers

Research demonstrates that prediction models incorporating 44 autoantibody markers, including anti-ANAPC15, can achieve significantly improved diagnostic performance with a specificity of 90.8% and sensitivity of 66.1% in total RA patients, and a true positive rate of 23.8% in ACPA-negative RA .

How can ANAPC15 antibodies be utilized to study cell cycle regulation mechanisms?

ANAPC15 antibodies provide powerful tools for investigating cell cycle regulation through several advanced techniques:

• Immunoprecipitation studies to isolate and characterize ANAPC15-containing complexes at different cell cycle stages

• Chromatin immunoprecipitation (ChIP) to identify potential DNA associations of ANAPC15-containing complexes

• Immunofluorescence microscopy combined with cell cycle markers to track ANAPC15 localization during mitotic progression

• Proximity ligation assays to detect and quantify in situ interactions between ANAPC15 and other APC/C components

• Flow cytometry with permeabilized cells to correlate ANAPC15 levels with cell cycle phases

These approaches can reveal the temporal and spatial dynamics of ANAPC15 function during normal cell cycle progression and in response to checkpoint activation. Given ANAPC15's role in promoting the turnover of CDC20 and MCC on the APC/C, these methods are particularly valuable for understanding how the spindle assembly checkpoint is regulated and resolved .

What are the technical challenges in detecting ANAPC15 in early-stage rheumatoid arthritis samples?

Detecting anti-ANAPC15 autoantibodies in early-stage rheumatoid arthritis presents several technical challenges:

• Heterogeneity of autoantibody responses: Research shows that autoantibody profiles in ACPA-negative RA patients are distinctly heterogeneous, making standardization difficult

• Varying titers across disease stages: Anti-ANAPC15 shows higher prevalence in early-stage RA (47.2% positive) compared to established RA, requiring assays with appropriate sensitivity for early detection

• Epitope specificity issues: Ensuring that detection antibodies recognize the same epitopes targeted by patient autoantibodies

• Sample processing variables: Standardizing collection, processing, and storage of serum samples to maintain autoantibody stability

• Cross-reactivity concerns: Distinguishing true anti-ANAPC15 responses from closely related autoantibodies

Despite these challenges, research demonstrates that anti-ANAPC15 shows promising performance in early-stage ACPA-negative RA, making resolution of these technical issues worthwhile for improving early diagnosis .

What methodological approaches can improve detection sensitivity for low-abundance ANAPC15 in complex biological samples?

Enhancing detection sensitivity for low-abundance ANAPC15 requires employing specialized methodological approaches:

• Signal amplification techniques:

  • Tyramide signal amplification for immunohistochemistry and immunofluorescence

  • Enhanced chemiluminescence with extended substrate exposure for Western blotting

  • Rolling circle amplification for ultrasensitive protein detection

• Sample enrichment strategies:

  • Subcellular fractionation to concentrate nuclear proteins where ANAPC15 predominantly localizes

  • Immunoaffinity enrichment using anti-ANAPC15 antibodies prior to analysis

  • Size-exclusion methods to separate ANAPC15 from more abundant proteins

• Advanced detection platforms:

  • Digital ELISA technologies that can detect proteins at femtomolar concentrations

  • Mass spectrometry-based targeted proteomics approaches with immunoprecipitation

  • Single-molecule counting methods for absolute quantification

These approaches can significantly improve detection limits for low-abundance ANAPC15, allowing its accurate quantification in complex biological matrices like tissue homogenates or patient serum samples .

How might research on ANAPC15 antibodies contribute to personalized medicine approaches in autoimmune diseases?

Research on ANAPC15 antibodies could advance personalized medicine in autoimmune diseases through several promising pathways:

• Patient stratification: The presence of anti-ANAPC15 autoantibodies could help identify distinct RA patient subgroups with potentially different disease mechanisms, prognoses, or treatment responses

• Targeted therapeutic development: Understanding the functional consequences of anti-ANAPC15 autoantibodies could reveal novel treatment targets specific to ACPA-negative RA

• Treatment response prediction: Monitoring anti-ANAPC15 levels before and during therapy might predict response to specific treatments

• Early intervention strategies: Given the higher prevalence of anti-ANAPC15 in early-stage RA (47.2% positive) compared to established disease, this marker could enable earlier therapeutic intervention

• Combination biomarker panels: Incorporating anti-ANAPC15 into multi-biomarker diagnostic models could significantly improve diagnostic accuracy for challenging cases

Research indicates that combining multiple autoantibody markers, including anti-ANAPC15, in a diagnostic model achieved 90.8% specificity with 66.1% sensitivity, demonstrating the potential for personalized diagnostic approaches in RA .

What emerging technologies might enhance ANAPC15 antibody development and application?

Several emerging technologies show promise for advancing ANAPC15 antibody development and applications:

• Single B-cell antibody cloning to develop monoclonal antibodies with unprecedented specificity for distinct ANAPC15 epitopes

• Recombinant antibody engineering to create fragment antibodies (Fab, scFv) with improved tissue penetration for imaging applications

• Nanobody development for smaller binding molecules capable of accessing restricted cellular compartments

• Multimodal imaging probes combining ANAPC15 antibodies with advanced imaging reporters (near-infrared fluorophores, MRI contrast agents)

• CRISPR-based epitope tagging of endogenous ANAPC15 to facilitate antibody validation and protein tracking in live cells

• Machine learning approaches to predict optimal antibody binding sites and improve antibody design

These technologies could revolutionize our ability to study ANAPC15 biology in both basic research and clinical applications, potentially leading to more sensitive and specific diagnostic tools .

How can multi-omics approaches incorporating ANAPC15 antibodies enhance our understanding of its role in disease mechanisms?

Integrating ANAPC15 antibody-based analyses into multi-omics frameworks can provide comprehensive insights into its role in disease mechanisms:

• Proteogenomic integration: Correlating ANAPC15 protein levels (detected via antibodies) with genomic alterations and transcriptomic data to identify regulatory mechanisms and discordances

• Spatial multi-omics: Combining ANAPC15 immunolocalization with spatial transcriptomics to understand tissue-specific contexts of ANAPC15 function

• Single-cell analysis: Integrating single-cell proteomics using ANAPC15 antibodies with single-cell RNA sequencing to capture cell-to-cell variability

• Temporal profiling: Tracking changes in ANAPC15 expression, localization, and interaction partners during disease progression

• Network analysis: Positioning ANAPC15 within protein interaction networks in specific disease contexts using antibody-based interactome studies

The genome-wide protein array approach used to identify anti-ANAPC15 autoantibodies in RA patients exemplifies how large-scale proteomic screening can reveal unexpected connections between cellular proteins and disease mechanisms. Future research combining antibody-based ANAPC15 detection with other omics approaches could further illuminate its role in autoimmune and cell cycle-related pathologies .